MISSION AND VISION
Our vision is to enable rapid and local tests for anticoagulants at the point-of-care to benefit patients.
Currently, there is no readily available solutions to address blood levels of the anticoagulants called Direct Oral Anticoagulants (DOACs) at the point-of-care.
We have developed a novel technology, chip and instrument that can detect DOACs, directly from whole blood within only 10 minutes. The elegant simplicity of our solution will provide a readily available test to use at individual departments at all hospitals.
OUR TECHNOLOGY
RAPID
Due to the novel technology the time from sample to readout is less than 10 min.
POINT-OF-CARE
The device is the small and thus fits in even the most hectic emergency room.
SIMPLE
No sample preparation is needed, simply add your sample and supplied calibrators and wait 10 min.
FOR INVESTORS
MedicQuant is currently fundraising.
We are looking for investment that enables us to mature our technology and business to reach the next value inflection points.
ABOUT US
MedicQuant ApS is a spin-out from Aarhus University founded in 2019. The technology was developed by the cofounders in the Gothelf Lab at Aarhus University. The company consists of CEO Line Debois, CTO Malthe Hansen-Bruhn and chair of the board Kurt Gothelf.
Supported by
